Business / Finance RSS Feed - Business / Finance

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer. [More]

Magnaquest inks PoC with leading pharma giant for Internet of Things related initiative

Magnaquest, a leading Subscription Management, Billing and CRM solutions for video, data and cloud computing operators has signed a Proof of Concept (PoC) with a leading pharma giant for Internet of Things (IoT) related initiative. [More]

Essilor to acquire Brazos Private Equity Partners’ portfolio company

Brazos Private Equity Partners, LLC, a leading Dallas-based private investment firm, today announced that it has agreed to sell its portfolio company, Vision Source, to Essilor of America, Inc., a subsidiary of Paris-based Essilor International and the leading manufacturer and wholesale distributor of optical lenses in the United States. [More]
Zimmer Biomet announces financial results for Q2 2015

Zimmer Biomet announces financial results for Q2 2015

Zimmer Biomet Holdings, Inc. today reported financial results for the quarter ended June 30, 2015. The Company reported second quarter net sales of $1.17 billion, a decrease of 1.3% reported and an increase of 5.7% constant currency compared to the second quarter of 2014. [More]
MiMedx Group reports record revenues and earnings for Q2 2015

MiMedx Group reports record revenues and earnings for Q2 2015

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the second quarter of 2015. [More]

HeartWare’s total revenues increase 13% to $73.6 million in second quarter 2015

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced total revenue of $73.6 million for the quarter ended June 30, 2015 compared to $70.1 million for the quarter ended June 30, 2014. [More]
Pantheon announces acquisition of IBSL

Pantheon announces acquisition of IBSL

Pantheon Holdco Ltd., doing business as the Pantheon Healthcare Group, announced today the acquisition of Ingegneria Biomedica Santa Lucia S.p.A., a key Italian-based provider of Clinical Engineering and a large range of biomedical equipment services, from Gruppo Giglio. [More]
Versatile accessory for bulk and flask freeze drying

Versatile accessory for bulk and flask freeze drying

SP Scientific has announced the Horizontal Drum Manifold - a new accessory to maximize the performance of its BenchTop Pro freeze dryer while adding bulk and flask drying capabilities for aqueous application. [More]
GE Healthcare to invest more than $1 billion over five years in enhanced training for healthcare professionals

GE Healthcare to invest more than $1 billion over five years in enhanced training for healthcare professionals

In developed countries like the U.S., Europe and parts of Asia, healthcare leaders are trying to optimize efficiency, systems integration, data analytics and achieve greater productivity. In emerging economies, enabling access to affordable, basic primary care is often the most pressing concern. Healthcare systems around the world face a wide range of difficult challenges. All could benefit from training and education solutions focused specifically on their particular needs. [More]
PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib). [More]
Mylan receives regulatory clearance from European Commission for proposed acquisition of Perrigo

Mylan receives regulatory clearance from European Commission for proposed acquisition of Perrigo

Mylan N.V. today announced that it received regulatory clearance from the European Commission under the European Union Merger Regulation (EUMR) for its proposed acquisition of Perrigo Company plc. [More]
Henry Schein reports net sales of $2.6 billion for second quarter 2015

Henry Schein reports net sales of $2.6 billion for second quarter 2015

Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today reported record second quarter financial results. [More]
CMC Biologics, River Vision sign manufacturing agreement for Teprotumumab to treat Grave's Orbitopathy

CMC Biologics, River Vision sign manufacturing agreement for Teprotumumab to treat Grave's Orbitopathy

CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy and other indications. [More]
Point-of-care diagnostics for Ebola

Point-of-care diagnostics for Ebola

In a recent DECODED research profile, Integrated DNA Technologies (IDT), details how IDT scientists Kristin Beltz and Dr Scott Rose are collaborating with Dr Brian Taylor’s research team at Battelle (Aberdeen, MD, USA) to design and validate a RT-qPCR assay that can detect the Ebola virus in the field. [More]

Sphere Medical publishes white paper discussing areas where Proxima mitigates sources of pre-analytical errors

Sphere Medical, innovator in critical care monitoring and diagnostics equipment, has published a white paper focusing on the mitigation of common pre-analytical errors associated with arterial blood gas analysis. [More]
Oxford Gene Technology expands portfolio of fluorescence in situ hybridisation probes

Oxford Gene Technology expands portfolio of fluorescence in situ hybridisation probes

Oxford Gene Technology (OGT), The Molecular Genetics Company, is extending its portfolio of Cytocell® Pathology FISH probes with the addition of eight new probes. OGT offers the widest range of fluorescence in situ hybridisation (FISH) probes on the market, delivering a cost-effective and reliable solution for anyone engaged in FISH. [More]
United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

United Therapeutics Corporation today announced its financial results for the second quarter ended June 30, 2015. "Orenitram sales grew nearly 300% as compared to the second quarter of 2014 when the product was first launched," said Roger Jeffs, Ph.D., United Therapeutics' President and Co-Chief Executive Officer. [More]
VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc., to support initial U.S. market entry of its NuQ colorectal cancer tests. [More]

Egalet declares pricing of underwritten public offering of common stock

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $11.25 per share. [More]
Centene reports strong financial results for Q2 2015

Centene reports strong financial results for Q2 2015

Centene Corporation today announced its financial results for the quarter ended June 30, 2015. The following discussions, with the exception of cash flow information, are in the context of continuing operations. [More]
Advertisement
Advertisement